CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0355 (clinicaltrials.gov NCT No: NCT00932698)
Title:An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Principal Investigator:Michael Wang
Treatment Agent:MLN9708
Study Status:Terminated
Study Description:The goal of this clinical research study is learn the highest tolerable dose of
MLN9708 that can be given to patients with MM. Researchers also want to learn
more about how MLN9708 works in the body. The safety of this drug will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:MLN9708
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:none
Supported By:Millennium Pharmaceuticals, Inc.
Return Visit:Patients will be administered MLN9708 orally on Days 1, 4, 8, and 11 during a
21-day
treatment cycle.
Home Care:no home care


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults